NEW YORK (GenomeWeb News) – Cancer molecular diagnostics firm Epigenomics said on Thursday that it intends to launch a capital raise in January in order to fund current operations and increase its distribution capabilities.

The company intends to raise just under €5 million ($6.6 million), which would allow it to avoid having to offer a prospectus under German securities laws, it said. The planned financing would extend the cash runway of Epigenomics to at least the fourth quarter of 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.